The bloc started jabs three weeks ago and has so far approved two vaccines -- from BioNTech/Pfizer and from Moderna -- with others soon expected to follow.
Last week authorities extended some COVID lockdown curbs until Jan. 18, including the temporary closure of hospitality venues and non-essential retailers.
The first daily vaccination statistics showed that nearly 2.3 million people had so far received their first doses of a COVID vaccine and nearly 400,000 had received a second dose.
The new daily death toll marks the fifth consecutive day that officials have reported more than 1,000 fatalities due to the highly contagious disease caused by the virus.
The new week-long stay at home orders affecting about 18 million people in Shijiazhuang and Xingtai come as cases spike ahead of the Lunar New Year, when hundreds of millions criss-cross the country to visit family and friends.
The EU began vaccinations on December 27 but the pace has been slow, with the Netherlands on Wednesday becoming the final country in the bloc to start.
The Bank of Israel said on Monday it expects the economy to rebound quickly in 2021 if the country's fast start to vaccinating people against COVID-19 is maintained.
Foreigners were net sellers of 74.1 billion won ($68.24 million) worth of shares on the main board, while retail investors purchased net 161.6 billion won.
But even then, Hungary on Saturday jumped the gun on the official roll-out by administering shots to frontline workers at hospitals in the capital Budapest.
"The data available to date showed a comparable high level of efficacy in all investigated age groups, thus meeting the safety requirements," it said on its website.
U.S. S&P 500 E-minis were up 1 point, or 0.03pc at 8:06 a.m. ET, Dow E-minis were up 6 points, or 0.02pc, while Nasdaq 100 E-minis were up 2.25 points, or 0.02pc.
The Food and Drug Administration is expected to issue formal approval Friday. This would make Moderna's vaccine the second to be approved in a Western country following the one developed by Pfizer-BioNTech.